Clinical trials to prevent Alzheimer's Disease in Down Syndrome

预防唐氏综合症中阿尔茨海默病的临床试验

• 批准号: 10249007
• 负责人: Michael S Rafii
• 金额: $ 99.84万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249007
• 关键词: Adult; Alzheimer' s Disease; Alzheimer' s disease pathology; Amyloid; Amyloid beta-42; Biological Assay; Biological Markers; Blood; Blood specimen; Clinical Trials; Cognition; Cognitive; Disease; Down Syndrome; Funding; Image; Impaired cognition; Individual; Measures; Medical; Outcome; Outcome Measure; Participant; Pathology; Plasma; Population; Positron-Emission Tomography; United States National Institutes of Health; blood-based biomarker; cohort; magnetic resonance imaging biomarker; prevent; tau Proteins; tau-1

TITLE: NIH INCLUDE ACTC-DS – Bringing Advances in Tau PET imaging and blood- based biomarkers of Phospho-tau to the Trial-Ready Cohort – Down Syndrome (TRC-DS) ABSTRACT With this supplement, we request funding to implement multiple new assays to be performed on CSF and blood samples as well as the addition of Tau PET imaging on half of the participants in the Alzheimer's Clinical Trial Consortium – Down Syndrome (ACTC-DS) Trial Ready Cohort – Down syndrome (TRC-DS) Project. Tau PET is a critical biomarker in understanding AD pathology in DS and as in the sporadic population, seems to correlate more closely with cognitive decline. Moreover, recent findings indicate that Pospho-Tau-217 (Ptau217) may represent perhaps the most accurate CSF- and blood-based biomarker of AD and will thus be critically important to study in the DS population.

标题：NIH包括ACTC-DS -带来Tau PET成像和血液-的进展

项目成果

Early-stage Alzheimer disease: getting trial-ready.

• DOI: 10.1038/s41582-022-00645-6
• 发表时间: 2022-07
• 期刊: Nature reviews. Neurology
• 作者: Aisen PS;Jimenez-Maggiora GA;Rafii MS;Walter S;Raman R
• 通讯作者: Raman R